- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01730560
Rehabilitation For Acquired Visual Field Defects: Development Of A Bottom-Up Approach (VISIOTRAIN)
Cortical Visual Field Defects (CFVD) are common after acquired brain injury. They often cause problems with reading and visual exploration which impact on patients' quality of life. Apart from the substitutive method that uses prisms directly placed on glasses, two main rehabilitative methods have been explored previously: one restorative and one compensatory. The most effective methods seem to be based on compensatory training paradigms that target eye movements. They rely on voluntary mass-practice that induces changes in exploratory saccadic behaviour, particularly into the blind hemifield. Previous studies using this method have shown changes in visual scanning patterns but with only a marginal profit in terms of functional benefit.
In the present study, the investigators developed a new approach to the compensatory visual field training based solely on a bottom-up mechanism. It does not require the patients' ability to voluntarily maintain attention oriented to the affected field, which may be difficult for brain-damaged patients. As previously reported in other pathological contexts (e.g. use of prism adaptation or sensory stimulation in neglect patients), bypassing voluntary and conscious implication of the patient can produce improvements by a more automatic process.
The investigators hypotheses are: 1) that a novel ramp-step search paradigm can be used by hemianopic patients to automatically improve targeted eye movements into their blind visual field; and 2) that this will lead to behavioural improvements on ecologically valid tests of visual search.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Saint Genis Laval, France, 69235
- Service de Médecine Physique et de Réadaptation,Hôpital Henry Gabrielle
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Male/Female
- Stroke (ischemia or hemorrhage) documented by CTscan or MRI
- Traumatic brain injury (TBI) documented by CTscan or MRI
- Right or Left hemianopia defined by perimetry
- All subjects must be between the ages of 18-80
- Aetiology of visual field defect : Stroke (ischemia or hemorrhage)
- Delay post-stroke : at least 6 months
- Only one lesion on CTscan or MRI (performed in a maximal delay of 6 months)
- Corrected monocular visual acuity > 5/10
- Possible understanding of experimental conditions
- Patient being able to be quiet and sit during at least 2 hours
- Having given written informed consent prior to any procedure related to the study
- Availability for the period of the study
- Covered by a Health System where applicable, and/or in compliance with the recommendations of the national laws in force relating to biomedical research
Exclusion Criteria:
- Ophthalmologic criteria : monocular visual acuity < 4/10, strabismus , diplopia , ocular instability , nystagmus, maculopathy , glaucoma , retinopathy , orthoptic rehabilitation
- Neurologic criteria : sever phasic disturbances , neurologic degenerative affection , non controlled seizure , severe handicap non compatible with prolonged sit position or concentration during 30 consecutive minutes
- No command of french language
- Non stabilized medical situation
- Females who are pregnant, nursing, or planning a pregnancy during the study period, or females of childbearing potential, not using a reliable means of contraception.
- Not under any administrative or legal supervision
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Arm 1:Treatment A
Treatment A (active) followed by treatment B (neutral)
|
The computer-based training task consists of a novel ramp-step search paradigm with a stimulus traversing the screen from left to right or right to left. Subjects are asked to pursue the stimulus (ramp phase) and then saccade to find its location when it suddenly jumps (step phase). The stimulus is an open spinning circle. At the end of each movement, the gap can be located at the top or at the bottom, and patients are asked to indicate this location by pushing the response button as quickly as possible. The starting point will alternate between left and right. The training task includes 3 sessions with 100 movements each. Reaction Times and errors will be monitored online to ensure that the patient performs the task correctly. Each treatment phase has the same pattern:
|
Experimental: Arm 2: Treatment B
Treatment B (neutral) followed by treatment A (active)
|
Placebo treatment using the same computer-based training task, but including only the ramp phase. Each treatment phase has the same pattern:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Difference in performance (mean reaction time - RT) of an ecological visual search task between pre-tests and immediate post-test for each patient according to treatment (A or B).
Time Frame: 1 week
|
1 week
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Errors and omissions at each evaluation session for the visual search task
Time Frame: 1, 2 and 5 weeks
|
Mean RT difference, errors and omissions at several visual tasks (rapid scanning task, exploratory visual tasks, reading task) at each evaluation session Parameters of visual field perimetry before and after treatment Oculo-motor parameters during the different tasks (i.e.
amplitude and latencies for saccades and fixations)
|
1, 2 and 5 weeks
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Sophie Jacquin-Courtois, MD, PhD, Service de Médecine Physique et de Réadaptation
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
- 2010.615
- 2010-A00702-37 (Other Identifier: ID-RCB)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Acquired Visual Field Defects
-
University Hospital TuebingenHaag-Streit AGCompleted
-
Haag Streit USATerminated
-
University Hospital Inselspital, BerneUniversity of BernCompletedVisual Field TestsSwitzerland
-
Vanderbilt University Medical CenterCompletedEstablishing a Normative Database in Pediatric Population of the Head-mounted visuALL Field AnalyzerVisual Field Defect, PeripheralUnited States
-
University Hospital Southampton NHS Foundation...University of SouthamptonCompleted
-
Massachusetts Eye and Ear InfirmaryNational Eye Institute (NEI)RecruitingHemianopia, Homonymous | Tunnel Vision | Visual Field Defect, Peripheral | Visual Field Constriction Bilateral | Visual Field Defect Homonymous BilateralUnited States
-
University of MiamiCompletedVisual Field Defect, Peripheral | Visual Field Defect, Nasal Step | Visual Field Defect, Paracentral Scotoma of Both EyesUnited States
-
Sun Yat-sen UniversityCompletedDiagnositic Efficacy of Deep Convolutional Neural Network in Differentiation of Glaucoma Visual Field From Non-glaucoma Visual FieldChina
-
Duke UniversityRecruitingVisual Field Defect, PeripheralUnited States
-
Rabin Medical CenterCompleted
Clinical Trials on Treatment A
-
PfizerCompletedA Bioequivalence (BE) Study Comparing The Commericializable And Clinical Formulations Of PF-00299804Healthy VolunteersBelgium
-
PfizerCompleted
-
PfizerCompleted
-
PfizerCompleted
-
PfizerCompletedHealthyUnited States
-
Novartis PharmaceuticalsCompleted
-
AstraZenecaParexelCompletedCoronary Artery DiseaseUnited Kingdom
-
Altamira Medica Ltd.CompletedRhinitis, Allergic | Perennial Allergic RhinitisCanada
-
PfizerCompleted